Biopharm Co. Sued In Del. Over Consent Right Ban
A shareholder is alleging Nektar Therapeutics has violated the law by preventing stockholders from taking action through written consent, and seeks to have a portion of the clinical-stage biopharmaceutical's bylaws declared...To view the full article, register now.
Already a subscriber? Click here to view full article